7-acetoxy-6-bromo-3-formylchromones, have an antimicrobial effect against staphylococcus and spore flora that do not affect intestinal flora
(57) Abstract:Usage: in medicine as an antimicrobial agent against staphyloccocus and spore flora that do not affect intestinal flora. Essence: 7-acetoxy-6-bromo-3-formylchromones. B. F. C12H7Br O5. So pl. 243oC. Reagent 1: 2-hydroxy-4-acetoxy-acetophenone. Reagent 2: complex Vilsmaier followed by cyclization. table 2. The invention relates to chemical-pharmaceutical industry, namely, to new biologically active substances on the basis of which can be created drugs that have antimicrobial activity.The claimed connection is a new derivative chromone, namely, 7-acetoxy-6-bromo-3-formylchromones
< / BR>Cited in the application connection properties and biological activity not described in literature.The closest structural analogues to the claimed compound are substituted chroman-3-aldehydes having antiallergic activity  Similar in structure and action is ocalenia acid 1-ethyl-1,4-dihydro-6,7 - methylenedioxy-4-oxoindole-3-carbon - Wai acid corresponding to the formula
used for infections of the Sabbath. The aim of the invention is to obtain a new derivative chromone, with more pronounced antimicrobial activity.The goal has been achieved by the synthesis of the compounds of formula
get beforeleaving 2-hydroxy-4 - acetoxystyrene complex of Vilsmeier with subsequent cyclization.P R I m e R 1. 7-Acetoxy-6-bromo-3-formylchromones.In a two-neck flask equipped with addition funnel, thermometer and potassium chloride tube, 20 ml of fresh N,N - dimethylformamide under ice cooling are added dropwise to 11.4 ml (0.05 M) of phosphorus oxychloride (U), then the mixture is left to stand for 30 min in the dark place. Then the flask on the magnetic stirrer and to the resulting reagent Vilsmeier under ice cooling and stirring, added dropwise a solution of 1.94 g (0.01 M) 2-hydroxy-4 - acetoxystyrene in 20 ml of DMF. The rate of addition of regulate so that the temperature did not rise above 10-15aboutC. Stirring is continued for another 1 h, then thickened the reaction mixture was poured into ice-cold water. The precipitation is sucked off over a Buechner funnel, washed with water until neutral and with three portions of cold ethanol (10 ml). The crude drug is dried and crystallized,8.Calculated From 46.3; H Of 2.26; Br 25,7; 25,7.The IR-spectrum, liquid paraffin: 1760 cm-1(ASO)
Number of state registration 10513192.Study of antimicrobial activity was carried out at the Department of physiology, pathology and Microbiology Pyatigorsk pharmaceutical Institute according to the following procedure:
In a sterile tube was placed a portion of the compounds, equal to 32 mg and dissolve it in 5 ml of DMSO, receiving a solution containing 6400 µg/ml of the substance. From the basic solution was prepared interim solution containing 1600 mcg/ml number of vials of sterile molten nutrient agar (20 ml in each vial) was added a measured amount of a primary or intermediate solution to obtain a concentration of the substance in the medium from 320 to 20 mcg/ml After mixing the contents of each vial were poured into a sterile Petri dish and after drying for 1 day was a series with decreasing concentrations of the drug in the medium and by sector produced seeding suspension 12 of the test cultures (listed in table 2) in the amount of one ear bacterial loop.Crops his crops on nutrient agar (PA) without drugs, nutrient agar with the addition of solvent, nutrient agar with the addition of norsulfazola and similar in structure and action of 7-hydroxy-6-bromo-4'-methoxyflavone. The research results of antimicrobial activity are shown in table. 1 and 2.Determination of acute toxicity and calculations LD50carried out according to the method of Cerberus  White mice weighing 20 g were injected intraperitoneally 0.5 ml of aqueous suspensions of the compounds. The suspension was prepared in Tween-80, at each dose in the experience took 6 mice.The results of these studies show that the claimed compound has a pronounced antimicrobial action, exceeding the activity norsulfazola (similar action) and 7 - hydroxy-6-bromo-4'-methoxyflavone (similar in structure and action).The claimed compound does not affect the growth of microorganisms of the intestinal-typeslogo family.This indicates the feasibility of further studies of this compound with the aim of creating effective drug. 7-Acetoxy-6-bromo-3-formylchromones formula
< / BR>have an antimicrobial effect against Staphylococcus and spore flora that do not affect intestinal flora.
FIELD: organic synthesis.
SUBSTANCE: invention provides compounds of general formula I:
, where R1 represents -CO-Ra, -SO2-Rb, or aryl optionally substituted by lower alkoxy, wherein Ra represents cycloalkyl, cycloalkyl(lower)alkyl, cycloalkyloxy, aryl, aryloxy, aryl(lower)alkyl, aryl(lower)alkoxy, aryloxy(lower)alkyl, aryl-S-(lower)alkyl, aryl(lower)alkenyl, provided that aryl group can be optionally substituted by halogen, lower alkyl, hydroxy, nitro, cyano, lower alkoxy, phenyl, CF3, cyano(lower)alkyl, lower alkyl-C(O)NH, lower alkyl-CO, and lower alkyl-S; heteroaryl, heteroaryl(lower)alkyl, or heteroaryl(lower)alkoxy, provided that heteroaryl group is 5- or 6-membered ring or bicyclic aromatic group constituted by two 5- or 6-membered rings including 1-3 heteroatoms selected from oxygen, nitrogen, and sulfur and that heteroaryl group can be optionally substituted by lower alkoxy; Rb represents aryl, aryl(lower)alkyl, or heteroaryl, aryl group optionally substituted by halogen, cyano, or lower alkyl-C(O)NH; R2 and R3 represent hydrogen atoms; R4 representshydrogen or lower alkyl; R5 represents hydrogen, lower alkyl, cycloalkyl, benzodioxyl, or aryl optionally substituted by lower alkyl, halogen, lower alkoxy, hydroxy, or (lower)alkyl-C(O)O; n is 1 or 2; and pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable esters thereof. Invention also provides a pharmaceutical composition exhibiting inhibitory activity with regard to cysteine proteases of the cathepsin family, which composition comprises compound of formula I, pharmaceutically acceptable recipient, and/or adjuvant.
EFFECT: increased choice of cysteine protease inhibitors.
34 cl, 1 tbl, 13 ex
FIELD: organic chemistry, chemical technology, medicine, biochemistry, pharmacy.
SUBSTANCE: invention relates to new derivatives of sulfonamides of the formula (I) or their pharmaceutically acceptable salts wherein R1 means -OH or -NHOH; R2 means hydrogen atom; R3 means alkyl, alkoxyalkyl, arylalkyl, pyridylalkyl or morpholinylalkyl; A means piperidyl or tetrahydrofuranyl; n = 0; E means a covalent bond; (C1-C4)-alkylene, -C(=O)-, -C(=O)O- or -SO2-; X means hydrogen atom, alkyl, aryl, arylalkyl, alkoxyalkyl, morpholinyl or tetrahydropyranyl; each among G and G' means -C(R5)=C(R5') wherein R5 and R5' mean hydrogen atom; M means the group -CH-; z means the group -(CR7R7')a-L-R8 wherein a = 0 and each among R7 and R7' means hydrogen atom; L means a covalent bond; R8 means halogen atom or alkoxy-group. Compounds of the formula (I) are inhibitors of metalloproteases and can be used for treatment of arthritis, cancer tumors and other diseases.
EFFECT: valuable medicinal properties of compounds.
15 cl, 7 tbl, 56 ex
SUBSTANCE: before applying substitute hormonal therapy (SHT) on should evaluate antithrombogenic activity of vascular wall in women. For this purpose one should determine quantitative values of ADP-induced aggregation of thrombocytes, activity of antithrombin III in blood and fibrinolytic blood activity both before and after "cuff"-test. Then one should detect the indices calculated as the ratio of mentioned values both before and after carrying out the mentioned test. If mentioned indices are decreased against the norm by 20-40% women should be prescribed to undergo SHT at additional introduction of aspirin and supradin. The method provides prophylaxis of cardio-vascular diseases in this category of female patients due to correcting affected functional activity of vascular endothelium.
EFFECT: higher efficiency of prophylaxis.
1 cl, 1 ex, 4 tbl
FIELD: medicine, natural compounds.
SUBSTANCE: larch wood is saturated with water and extraction with ethyl acetate is carried out. Prepared extract is treated with hot water and this process is combined with distilling off a solvent. Then water-insoluble resin impurities are separated and crude product is isolated by crystallization and recrystallized. Invention provides simplifying the process.
EFFECT: improved preparing method.
FIELD: medicine, pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to compositions used for treatment and/or prophylaxis of chlamydium infections caused by C. pheumoniae. Pharmaceutical composition used for treatment and/or prophylaxis of chlamydium infection caused by C. pneumoniae comprises the taken phenolic compound, or extract, or fraction, or incomplete fraction comprising the taken phenolic compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction obtained from plants and comprising indicated compound or corresponding synthetic compound on C. pneumoniae represents the definite percent of inhibition for formation of inclusions. The composition useful for health eliciting an anti-chlamydium effect with respect to C. pneumoniae comprises the taken phenolic compound or extract, or fraction, or incomplete fraction containing indicated compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent for inhibition in formation of inclusions. Also, invention relates to applying the composition useful for health in preparing foodstuffs or as supplements for nutrition for every day. Also, invention relates to applying phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound or mixture of indicated compounds obtained from plants in manufacturing a medicinal agent used for treatment and/or prophylaxis of chlamydium infections caused by C. pneumoniae. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent in inhibition in formation of inclusions. Compositions promote to effective prophylaxis and treatment of chlamydium infections caused by C. pneumoniae.
EFFECT: valuable medicinal properties of compounds.
21 cl, 1 dwg, 1 tbl, 6 ex